{
    "clinical_study": {
        "@rank": "166593", 
        "arm_group": [
            {
                "arm_group_label": "Sequence A", 
                "arm_group_type": "Experimental", 
                "description": "Treatment 1 - Treatment 2 - Treatment 3"
            }, 
            {
                "arm_group_label": "Sequence B", 
                "arm_group_type": "Experimental", 
                "description": "Treatment 1 - Treatment 3 - Treatment 2"
            }, 
            {
                "arm_group_label": "Sequence C", 
                "arm_group_type": "Experimental", 
                "description": "Treatment 2 - Treatment 1 - Treatment 3"
            }, 
            {
                "arm_group_label": "Sequence D", 
                "arm_group_type": "Experimental", 
                "description": "Treatment 2 -  Treatment 3 - Treatment 1"
            }, 
            {
                "arm_group_label": "Sequence E", 
                "arm_group_type": "Experimental", 
                "description": "Treatment 3 - Treatment 1 - Treatment 2"
            }, 
            {
                "arm_group_label": "Sequence F", 
                "arm_group_type": "Experimental", 
                "description": "Treatment 3 - Treatment 2 - Treatment 1"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and pharmacokinetics/pharmacodynamics of\n      co-administration of Clomipramine HCl 15mg and Sildenafil citrate 100mg compared to the\n      effects after single oral administration in Korean healthy male volunteers."
        }, 
        "brief_title": "Drug-Drug Interaction of Clomipramine HCl and Sildenafil Citrate in Healthy Males", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Clomipramine is a dibenzazepine-derivative tricyclic antidepressant (TCA) and is a  potent\n      inhibitor of serotonin and norepinephrine reuptake. Clomipramine may be used in a variety of\n      indications. Condencia Tab contains low dose of 15mg of clomipramine HCl as an active\n      ingredient, which is newly approved to market for the treatment of premature ejaculation.\n\n      This study is a prospective, randomised, open-labeled, 6-sequence, 3-period, 3-treatment,\n      crossover, and single-center clinical trial. A total of 30 healthy male volunteers will be\n      enrolled and randomised into one among 6 groups (5 subjects per a group).  The safety and\n      PK/PD characteristics of co-administration of Clomipramine HCl and Sildenafil citrate will\n      be investigated closely compared to the effects after single dose administrations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Korean healthy males aged between 19 and 65\n\n          -  Body weight between 60kg and 90kg, BMI between 19 and 27\n\n          -  Given informed consent\n\n        Exclusion Criteria:\n\n          -  Clinically significant medical history and/or concurrent disease\n\n          -  SBP >=140 mmHg or <=90 mmHg, DBP >=95 mmHg or <=50 mmHg\n\n          -  Orthostatic hypotension\n\n          -  Hypersensitivity to any ingredient of investigational drugs\n\n          -  Severe bleeding or blood donation within 8 weeks prior to study participation\n\n          -  Alcoholism or drug abuser\n\n          -  Smoking more than 0.5 pack-year\n\n          -  Persistent alcohol consumption more than 21 units(210g)/week\n\n          -  Participation in other investigational clinical trial"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028598", 
            "org_study_id": "CTC-PED-DDI-1"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D", 
                    "Sequence E", 
                    "Sequence F"
                ], 
                "description": "An oral single dose administration", 
                "intervention_name": "Treatment 1", 
                "intervention_type": "Drug", 
                "other_name": "Clomipramine HCl 15mg (Condencia Tab)"
            }, 
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D", 
                    "Sequence E", 
                    "Sequence F"
                ], 
                "description": "An oral single dose administration", 
                "intervention_name": "Treatment 2", 
                "intervention_type": "Drug", 
                "other_name": "Sildenafil citrate 100mg (Viagra Tab)"
            }, 
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D", 
                    "Sequence E", 
                    "Sequence F"
                ], 
                "description": "Co-administration of oral single doses", 
                "intervention_name": "Treatment 3", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Clomipramine HCl 15mg (Condencia Tab)", 
                    "Sildenafil citrate 100mg (Viagra Tab)"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clomipramine", 
                "Citric Acid", 
                "Sildenafil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Clomipramine", 
            "Premature ejaculation"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Yangji Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Open-labeled, 6-sequence, 3-period, 3-treatment Crossover Study to Evaluate the Effect of Co-administration of Clomipramine HCl (Condencia Tab.) 15mg and Sildenafil Citrate (Viagra Tab.) 100mg on the Safety and Pharmacokinetic/Pharmacodynamic Properties of Clomipramine and Sildenafil Compared to the Effects After Single Oral Administration in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Yangji Hospital", 
            "last_name": "Yun Hi Kang, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The systemic exposure measured as area under the curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "From Day 1(dosing) to Day 4(72hrs)"
            }, 
            {
                "measure": "The maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "From Day 1(dosing) to Day 4(72hrs)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028598"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Including Tmax, T1/2, AUCnorm, Cmax norm, CL/f and Cmax/AUC", 
                "measure": "Pharmacokinetic parameters except the primary endpoints", 
                "safety_issue": "No", 
                "time_frame": "From Day 1(dosng) to Day 4(72hrs)"
            }, 
            {
                "description": "At supine and upright positions", 
                "measure": "The maximum change of systolic blood pressures within 12hrs after dosing", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1(dosing) to Day 2(12hrs)"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "For 3 Weeks after dosing"
            }, 
            {
                "description": "at supine and upright positions", 
                "measure": "The maximum change of dystolic blood pressure within 12hrs after dosing", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1(dosing) to Day 2(12hrs)"
            }, 
            {
                "description": "At supine and upright positions", 
                "measure": "The maximum change of heart rates within 12 hours after dosing", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1(dosing) to Day 2(12hrs)"
            }, 
            {
                "description": "Clinically significant changes will be classified into 4 groups: SBP change >=30 or 20 mmHg, DBP change >= 20 or 10 mmHg (at supine and upright positions)", 
                "measure": "The rate of the subjects who experienced the clinically significant change of blood pressures", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1(dosing) to Days 2(12hrs)"
            }
        ], 
        "source": "CTC Bio, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Symyoo", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "CTC Bio, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}